{"protocolSection":{"identificationModule":{"nctId":"NCT00442325","orgStudyIdInfo":{"id":"A2581095"},"organization":{"fullName":"Pfizer","class":"INDUSTRY"},"briefTitle":"Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets","officialTitle":"ACTFAST (2): Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration: A Multicenter, Twelve-Week Treatment, Single-Step Titration, Open-Label Study Assessing The Percentage Of Dyslipidemic High-Risk Patients Achieving Low Density Lipoprotein Cholesterol (LDL-C) Target With Atorvastatin Starting Doses Of 10 mg, 20 mg, 40 mg, And 80 mg.","acronym":"ACTFAST 2"},"statusModule":{"statusVerifiedDate":"2021-02","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2003-01"},"completionDateStruct":{"date":"2004-02"},"studyFirstSubmitDate":"2007-02-28","studyFirstSubmitQcDate":"2007-02-28","studyFirstPostDateStruct":{"date":"2007-03-01","type":"ESTIMATED"},"lastUpdateSubmitDate":"2021-02-17","lastUpdatePostDateStruct":{"date":"2021-02-18","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"European physicians tend to always use the lowest dose of statins to initiate therapy even in subjects who require large reductions in cholesterol. The study evaluates if selecting the starting dose based on baseline and target LDL-C cholesterol would provide better results (ie proportion of subjects resching target)"},"conditionsModule":{"conditions":["Coronary Arteriosclerosis","Diabetes Mellitus, Type 2","Cerebrovascular Accident","Dyslipidemia","Peripheral Vascular Disease"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":595}},"armsInterventionsModule":{"interventions":[{"type":"DRUG","name":"Atorvastatin (Lipitor)"}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Proportion of subjects achieving a LDL-C target of < 100 mg/dL (2.6 mmol/L) after 12 weeks."}],"secondaryOutcomes":[{"measure":"Percentage of subjects achieving:"},{"measure":"LDL-C target <100 mg/dL (<2.6 mmol/L) after 6 weeks of treatment."},{"measure":"Total cholesterol (TC)/HDL-C ratio target (<4.0) after 6 and 12 weeks of treatment."},{"measure":"Either the LDL-C <100mg/dL (<2.6 mmol/L) or TC/HDL-C ratio (<4.0) targets after 6 and 12 weeks of treatment."},{"measure":"Both the LDL-C <100mg/dL (<2.6 mmol/L) and TC/HDL-C ratio (<4.0) targets after 6 and 12 weeks of treatment."},{"measure":"LDL-C <100mg/dL (<2.6 mmol/L) or TC/HDL-C ratio (<4.0) targets after 6 and 12 weeks of treatment by LDL-C strata."},{"measure":"LDL-C target (<100 mg/dL) by primary inclusion diagnosis (CHD, CHD-equivalent, diabetes or 10-year CHD risk-equivalent >20%)."},{"measure":"The mean percent change in LDL-C, high density lipoprotein cholesterol (HDL-C),TC/HDL-C ratio, non HDL-C (in subjects with triglycerides [TG] ≥200 mg/dL or 2.3 mmol/L), TC and TG from baseline to 6 and 12 weeks of treatment. Change from baseline in apol"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* High cholesterol blood levels (LDL-cholesterol above 100 mg/dL up to 220 mg/dL.\n* Triglycerides up to 600 mg/dL.\n* History of coronary artery disease (ex.: heart attack, angina), stroke, diabetes or at high risk of such events.\n\nExclusion Criteria:\n\n* Pregnancy or lactation, use of high statin doses (\\>40mg) at baseline, liver or renal problems\n* Use of other drugs that would interfere with evaluation of efficacy or cause safety problems\n* Uncontrolled hypertension, diabetes or hypothyroidism\n* Recent cardiac event of procedure\n* High baseline CPK levels","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Pfizer CT.gov Call Center","affiliation":"Pfizer","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Pfizer Investigational Site","city":"Ioannina","country":"Greece","geoPoint":{"lat":39.66486,"lon":20.85189}},{"facility":"Pfizer Investigational Site","city":"Kallithea, Athens","country":"Greece"},{"facility":"Pfizer Investigational Site","city":"Pireaus","country":"Greece"},{"facility":"Pfizer Investigational Site","city":"Thessaloniki","country":"Greece","geoPoint":{"lat":40.64361,"lon":22.93086}},{"facility":"Pfizer Investigational Site","city":"Budapest","country":"Hungary","geoPoint":{"lat":47.49801,"lon":19.03991}},{"facility":"Pfizer Investigational Site","city":"Gyula","country":"Hungary","geoPoint":{"lat":46.65,"lon":21.28333}},{"facility":"Pfizer Investigational Site","city":"Kecskemet","country":"Hungary","geoPoint":{"lat":46.90618,"lon":19.69128}},{"facility":"Pfizer Investigational Site","city":"Nyíregyháza","country":"Hungary","geoPoint":{"lat":47.95539,"lon":21.71671}},{"facility":"Pfizer Investigational Site","city":"Szekszárd","country":"Hungary","geoPoint":{"lat":46.35014,"lon":18.70905}},{"facility":"Pfizer Investigational Site","city":"Tullamore","state":"CO. Offlay","country":"Ireland","geoPoint":{"lat":53.27389,"lon":-7.48889}},{"facility":"Pfizer Investigational Site","city":"Tallaght","state":"Dublin","country":"Ireland","geoPoint":{"lat":53.2859,"lon":-6.37344}},{"facility":"Pfizer Investigational Site","city":"Gorey","state":"Wexford","country":"Ireland","geoPoint":{"lat":52.67472,"lon":-6.2925}},{"facility":"Pfizer Investigational Site","city":"Cork","country":"Ireland","geoPoint":{"lat":51.89797,"lon":-8.47061}},{"facility":"Pfizer Investigational Site","city":"Dublin 8","country":"Ireland","geoPoint":{"lat":53.33306,"lon":-6.24889}},{"facility":"Pfizer Investigational Site","city":"Dublin","country":"Ireland","geoPoint":{"lat":53.33306,"lon":-6.24889}},{"facility":"Pfizer Investigational Site","city":"Galway","country":"Ireland","geoPoint":{"lat":53.27194,"lon":-9.04889}},{"facility":"Pfizer Investigational Site","city":"Czestochowa","country":"Poland","geoPoint":{"lat":50.79646,"lon":19.12409}},{"facility":"Pfizer Investigational Site","city":"Poznan","country":"Poland","geoPoint":{"lat":52.40692,"lon":16.92993}},{"facility":"Pfizer Investigational Site","city":"Warszawa","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Pfizer Investigational Site","city":"Wroclaw","country":"Poland","geoPoint":{"lat":51.1,"lon":17.03333}},{"facility":"Pfizer Investigational Site","city":"Zabrze","country":"Poland","geoPoint":{"lat":50.32492,"lon":18.78576}},{"facility":"Pfizer Investigational Site","city":"Aveiro","country":"Portugal","geoPoint":{"lat":40.64427,"lon":-8.64554}},{"facility":"Pfizer Investigational Site","city":"Lisboa","country":"Portugal","geoPoint":{"lat":38.71667,"lon":-9.13333}},{"facility":"Pfizer Investigational Site","city":"Porto","country":"Portugal","geoPoint":{"lat":41.14961,"lon":-8.61099}},{"facility":"Pfizer Investigational Site","city":"Vila Franca de Xira","country":"Portugal","geoPoint":{"lat":38.95525,"lon":-8.98966}},{"facility":"Pfizer Investigational Site","city":"Moscow","country":"Russian Federation","geoPoint":{"lat":55.75222,"lon":37.61556}},{"facility":"Pfizer Investigational Site","city":"Bratislava","country":"Slovakia","geoPoint":{"lat":48.14816,"lon":17.10674}},{"facility":"Pfizer Investigational Site","city":"Kosice","country":"Slovakia","geoPoint":{"lat":48.71395,"lon":21.25808}},{"facility":"Pfizer Investigational Site","city":"Bern","country":"Switzerland","geoPoint":{"lat":46.94809,"lon":7.44744}},{"facility":"Pfizer Investigational Site","city":"Genève","country":"Switzerland","geoPoint":{"lat":46.20222,"lon":6.14569}},{"facility":"Pfizer Investigational Site","city":"Mendrisio","country":"Switzerland","geoPoint":{"lat":45.87019,"lon":8.9816}},{"facility":"Pfizer Investigational Site","city":"Zürich","country":"Switzerland","geoPoint":{"lat":47.36667,"lon":8.54999}},{"facility":"Pfizer Investigational Site"}]},"referencesModule":{"references":[{"pmid":"17626713","type":"DERIVED","citation":"Farsang C, Athyros V, Gaw A; ACTFAST-2 investigators and Steering Committee members. A multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL-C levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST-2) study. Curr Med Res Opin. 2007 Aug;23(8):1945-56. doi: 10.1185/030079907X223242."}],"seeAlsoLinks":[{"label":"To obtain contact information for a study center near you, click here.","url":"https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A2581095&StudyName=Benefits+Of+Using+Various+Starting+Doses+Of+Atorvastatin+On+Achievement+Of+Cholesterol+Targets+%28ACTFAST+2%29"}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000016491","term":"Peripheral Vascular Diseases"},{"id":"D000058729","term":"Peripheral Arterial Disease"},{"id":"D000001161","term":"Arteriosclerosis"},{"id":"D000003324","term":"Coronary Artery Disease"},{"id":"D000017202","term":"Myocardial Ischemia"},{"id":"D000003924","term":"Diabetes Mellitus, Type 2"},{"id":"D000050171","term":"Dyslipidemias"}],"ancestors":[{"id":"D000003920","term":"Diabetes Mellitus"},{"id":"D000044882","term":"Glucose Metabolism Disorders"},{"id":"D000008659","term":"Metabolic Diseases"},{"id":"D000004700","term":"Endocrine System Diseases"},{"id":"D000052439","term":"Lipid Metabolism Disorders"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000050197","term":"Atherosclerosis"},{"id":"D000001157","term":"Arterial Occlusive Diseases"},{"id":"D000003327","term":"Coronary Disease"},{"id":"D000006331","term":"Heart Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Cerebrovascular Accident","relevance":"HIGH"},{"id":"M6805","name":"Diabetes Mellitus","relevance":"LOW"},{"id":"M6809","name":"Diabetes Mellitus, Type 2","asFound":"Diabetes Mellitus, Type 2","relevance":"HIGH"},{"id":"M6236","name":"Coronary Artery Disease","asFound":"Coronary Arteriosclerosis","relevance":"HIGH"},{"id":"M25871","name":"Dyslipidemias","asFound":"Dyslipidemia","relevance":"HIGH"},{"id":"M19196","name":"Myocardial Ischemia","asFound":"Coronary Arteriosclerosis","relevance":"HIGH"},{"id":"M28903","name":"Peripheral Arterial Disease","asFound":"Peripheral Vascular Disease","relevance":"HIGH"},{"id":"M18584","name":"Peripheral Vascular Diseases","asFound":"Peripheral Vascular Disease","relevance":"HIGH"},{"id":"M17090","name":"Vascular Diseases","asFound":"Vascular Disease","relevance":"HIGH"},{"id":"M4159","name":"Arteriosclerosis","asFound":"Arteriosclerosis","relevance":"HIGH"},{"id":"M6239","name":"Coronary Disease","relevance":"LOW"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M11329","name":"Metabolic Diseases","relevance":"LOW"},{"id":"M25093","name":"Glucose Metabolism Disorders","relevance":"LOW"},{"id":"M7552","name":"Endocrine System Diseases","relevance":"LOW"},{"id":"M26719","name":"Lipid Metabolism Disorders","relevance":"LOW"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M25878","name":"Atherosclerosis","relevance":"LOW"},{"id":"M4155","name":"Arterial Occlusive Diseases","relevance":"LOW"},{"id":"M9109","name":"Heart Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC18","name":"Nutritional and Metabolic Diseases"},{"abbrev":"BC19","name":"Gland and Hormone Related Diseases"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000069059","term":"Atorvastatin"}],"ancestors":[{"id":"D000000924","term":"Anticholesteremic Agents"},{"id":"D000000960","term":"Hypolipidemic Agents"},{"id":"D000000963","term":"Antimetabolites"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000057847","term":"Lipid Regulating Agents"},{"id":"D000019161","term":"Hydroxymethylglutaryl-CoA Reductase Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"}],"browseLeaves":[{"id":"M351","name":"Atorvastatin","asFound":"Functional","relevance":"HIGH"},{"id":"M3933","name":"Anticholesteremic Agents","relevance":"LOW"},{"id":"M3968","name":"Hypolipidemic Agents","relevance":"LOW"},{"id":"M3971","name":"Antimetabolites","relevance":"LOW"},{"id":"M28573","name":"Lipid Regulating Agents","relevance":"LOW"},{"id":"M20845","name":"Hydroxymethylglutaryl-CoA Reductase Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"}],"browseBranches":[{"abbrev":"Lipd","name":"Lipid Regulating Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}